Skip to content

Xencor teams up with MD Anderson on XmAb cancer treatments

September 3, 2020

Xencor (NASDAQ:XNCR) will collaborate with The University of Texas MD Anderson Cancer Center to investigate treatments for a range of cancers leveraging the company’s line-up of XmAb drug candidates, including novel bispecific antibodies and engineered cytokines.

The company will fund and support clinical studies over an initial five-year term.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: